Nanomerics - Pharmaceutical Nanotechnology

“Nanomerics uses leading know-how in pharmaceutical nanotechnology to overcome the limitations of current medicines and develop products that deliver patient benefit in areas of unmet medical need.”

Nanomerics' Oral Amphotericin B Promises Better Treatment for Millions

www.who.int/entity/leishmaniasis/Leish_viscerial.jpgNanomerics has developed a nano-enabled orally active form of Amphotericin B which could provide improved access to efficacious therapy to millions of people affected by Leishmaniasis.

Nanomerics Announces Completion of Major Preclinical Toxicology Programme on its Molecular Envelope Technology

Nanomerics today announced the successful completion of a major preclinical toxicology programme on its Molecular Envelope Technology (MET), paving the way for the technology’s clinical testing.  Safety pharmacology, mutagenicity and a range of 28 day repeat dose Good Laboratory Practice (GLP) standard toxicology tests have been completed on two species (rodent and non-rodent).

Fighting Fit - Nanomerics featured in CBI Business Voice Publication

moleculesIn the October edition of the CBI's  online publication 'Business Voice' journalist Dan Jellinek looks at how leading UK innovators contribute to the expanding UK life science sector. Nanomerics' CEO Prof Andreas Schatzlein describes how support from the EPSRC,  the Wellcome Trust, and Innovate UK has helped Nanomerics to translate scientific research into medicines which bring important patient benefits.

Prof Martin Koltzenburg Joins Nanomerics Advisory Board

Nanomerics is pleased to announce the strengthening of its Scientific Advisory Board with the appointment of Professor Martin Koltzenburg.  Professor Koltzenburg’s appointment will  support the clinical development of iNanomerics' lead product NM0127, a novel pain therapeutic based on an endogenous peptide.  


www.uclh.nhs.uk/OurServices/Consultants/PublishingImages/KoltzenburgMartin.jpg

Antibodies to the Brain - A High Impact Collaboration

Nanomerics is embarking on a new EPSRC funded collaborative research project with the Danish pharmaceutical company H Lundbeck, UCL, and Exeter University.  

LogosAs part of the new collaboration, the company aims to develop new and exciting ways to deliver antibodies to the brain, building on the molecular envelope technology Nanomerics has developed to deliver previously undeliverable drugs to the organ.
 

UCL’s School of Life and Medical Sciences Celebrates Enterprise Successes

UCL Enterprise publicationSpin-out Nanomerics and its founders were highlighted in UCL’s School of Life and Medical Sciences recently launched  'Enterprise' publication. The brochure, available here, celebrates recent success stories of translation of scientific knowledge. 

Dr Alan Bye joins Nanomerics' Board of Directors.

logoNanomerics is pleased to announce the appointment of Dr Alan Bye to Nanomerics' Board of Directors.  Alan Bye is an experienced and accomplished pharmaceutical scientist who previously ran GSK's Centre of Excellence in Neuroscience.  Dr Bye has taken numerous products from concept to market and brings valuable industrial and product development experience to the board.

Nanomerics new patent granted in Japan

 Nanomerics is pleased to announce that a Notice of Allowance has been received on one of its key MET patents - Japanese Patent  JP5469458. Nanomerics' CEO, Dr Andreas Schatzlein says, "we are delighted with this notice of allowance from the Japanese Patent Office.  This further strengthen's our MET patent estate and enables us to work  in a major and lucrative market".

MET Fibrous Hydrogel
MET Fibrous Hydrogel
Subscribe to Nanomerics RSS